Annovis Bio, Inc. (ANVS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$14.2M
Cash & Equivalents
$9.0M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$79M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06709014 | A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | PHASE3 | Active Not Recruiting | 760 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-10 | 8-K | Annovis Bio, Inc. (ANVS) (CIK 0001477845) - EXHIBIT 99.1 | EDGAR |